Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
about
Clinical Overview of MDM2/X-Targeted TherapiesP53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic LeukemiaPre-clinical validation of a selective anti-cancer stem cell therapy for Numb-deficient human breast cancers.Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.The role of MDM2 and MDM4 in breast cancer development and prevention.MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer.E3 ubiquitin ligase Cbl-b activates the p53 pathway by targeting Siva1, a negative regulator of ARF, in FLT3 inhibitor-resistant acute myeloid leukemiaInduced protein degradation: an emerging drug discovery paradigm.How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097Regain control of p53: Targeting leukemia stem cells by isoform-specific HDAC inhibitionThe Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.Ibrutinib synergizes with MDM-2 inhibitors in promoting cytotoxicity in B chronic lymphocytic leukemia.MDM2 is a potential therapeutic target and prognostic factor for ovarian clear cell carcinomas with wild type TP53.Dysfunction of the MDM2/p53 axis is linked to premature aging.Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.Identifying novel therapeutic agents using xenograft models of pediatric cancer.Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.Pharmacological activation of wild-type p53 in the therapy of leukemia.MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.Induction of p53 suppresses chronic myeloid leukemia.Reviving the guardian of the genome: Small molecule activators of p53.Understanding cell cycle and cell death regulation provides novel weapons against human diseases.Chronic lymphocytic leukaemia genomics and the precision medicine era.TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiationSynergistic targeting of malignant pleural mesothelioma cells by MDM2 inhibitors and TRAIL agonists.The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphomaAcute myeloid leukemia patients' clinical response to idasanutlin (RG7388) is associated with pre-treatment MDM2 protein expression in leukemic blasts.Structural analysis of MDM2 RING separates degradation from regulation of p53 transcription activity.Identification of the SOX2 Interactome by BioID Reveals EP300 as a Mediator of SOX2-dependent Squamous Differentiation and Lung Squamous Cell Carcinoma Growth.MDM2 Antagonists Counteract Drug-Induced DNA Damage.Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate.Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.Targeting apoptosis in acute myeloid leukaemia.High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.The Role of MDM2 in Promoting Genome Stability versus Instability.ClinGen Cancer Somatic Working Group - standardizing and democratizing access to cancer molecular diagnostic data to drive translational research.Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report.Inhibition of MDM2 by a rhein-derived compound AQ-101 suppresses cancer development in SCID mice.Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others.
P2860
Q26767402-3309C342-8723-4D0B-83AE-D59B2666522BQ28078609-5BAEB6BA-1405-4577-9804-2E8CF0F88B49Q33626025-E9829660-AC9A-4057-84E9-8DC613F7E0DAQ33699808-1B29D074-A87D-48ED-8023-68F7937BB1B2Q33712095-049967CD-3DF4-43D0-9D75-6C12CEAFC785Q33869257-06F70CC0-EF15-49A1-AE69-927F4A6F3697Q33903412-ED8CEC8D-C46A-47E3-B7C5-3FD9E2AE25ECQ34545841-BC4DC09A-BE74-474E-9D46-471EF4657405Q35871210-B93B7018-8A41-4EF8-8F7E-D2192F6F7E2BQ36132787-E634E30F-1EF0-4062-8190-52BBE032FC8EQ36827373-91F80A49-BD1B-4242-95B0-09E792008F0BQ37526352-DD791E69-D612-4629-9740-ECAB7F6C6CB7Q37688589-F6880E6C-DC03-488B-BDA1-317B605B90A6Q37688946-179352CE-B450-4470-9EF7-63050E960B23Q38605937-2EC086DF-AC3F-4630-841F-21E39C15B331Q38760193-4A45705C-86EE-4C0B-8E03-6F72CBB035A5Q38837564-B920521A-4E8F-4602-97E3-8399F95738F6Q38865504-4F3F4402-B9F0-44ED-8A47-F67DF766F759Q38872029-2F3C1855-5143-4AE9-9542-BF8206614CA4Q38997002-4ED55E70-D07A-4C68-AA75-EC2FAB490DD7Q39022440-E8C7736D-ECDC-4F06-B7DB-2EDD8B619639Q39205536-E9A7A101-64D1-4EC3-921D-C66E47B02378Q39218376-EE67D3B6-E6B4-4B79-8DA3-369D2C275091Q39263974-67F363C7-E462-432B-9A00-CF47FF18524AQ40854245-3A938EFF-9CC7-46DE-9944-E6A2EF5200A8Q41279899-78E25CB8-C351-4A0A-A82F-86C2F3A571B8Q42070740-73709C3F-632D-4EBB-A31F-DB153E72A473Q42399875-CF9E2750-F421-4C8D-A585-C33A693CCAB0Q42510354-A250D182-0098-4431-9E61-357403F08C10Q42513461-64E18509-482D-46DE-B996-614F0EA6F27BQ42651903-50970408-EC6F-40D1-AC98-C85465298853Q42832493-F6FCBE8D-54E9-4FE9-AE25-DED98DB5FB59Q44176860-ED18FB36-3AC1-48AB-8F9E-636210051CC8Q44489428-AF3D40EC-0181-413D-B72B-C2CA770521AFQ45120868-FFAC8F91-D51B-4A02-AE19-2F9896BBE2D6Q47096280-0A3194EA-AEF2-415E-9EDB-9CC70787583CQ47124495-A0071E16-5DB1-4689-9E83-5B022FEB4650Q47153881-C18DEBE7-4835-4176-A5C8-78B19BF636E0Q47251018-2F55397C-3EE5-4060-B94C-353BAE9D3047Q47742599-25E4254B-FC51-4AE7-84FA-D6AE74DF0582
P2860
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
@ast
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
@en
type
label
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
@ast
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
@en
prefLabel
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
@ast
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
@en
P2093
P2860
P50
P1476
Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.
@en
P2093
Bradford Graves
David Bowen
Graciela M Nogueras González
Gwen Nichols
Jianguo Zhi
Kensuke Kojima
Kevin R Kelly
Leslie Popplewell
P2860
P304
P356
10.1158/1078-0432.CCR-15-0481
P407
P577
2015-10-12T00:00:00Z